
Thomas R Einarson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9031638/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovascular Diabetology, 2018, 17, 83.	2.7	1,198
2	Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology, 2000, 62, 385-392.	1.7	823
3	Paroxetine and congenital malformations: Meta-Analysis and consideration of potential confounding factors. Clinical Therapeutics, 2007, 29, 918-926.	1.1	214
4	Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiology and Drug Safety, 2005, 14, 823-827.	0.9	202
5	Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review. Value in Health, 2018, 21, 881-890.	0.1	190
6	An Overview of Topical Antifungal Therapy in Dermatomycoses. Drugs, 1998, 55, 645-674.	4.9	117
7	Pregnancy outcome following maternal organic solvent exposure: A meta-analysis of epidemiologic studies. , 1998, 34, 288-292.		97
8	Probiotic Safety in Pregnancy: A Systematic Review and Meta-analysis of Randomized Controlled Trials of Lactobacillus, Bifidobacterium, and Saccharomyces spp Journal of Obstetrics and Gynaecology Canada, 2009, 31, 542-552.	0.3	84
9	Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis. Journal of Population Therapeutics and Clinical Pharmacology, 2013, 20, e171-83.	1.4	62
10	Does Paroxetine Cause Cardiac Malformations?. Journal of Obstetrics and Gynaecology Canada, 2008, 30, 696-701.	0.3	51
11	Hospital-wide Rollout of Antimicrobial Stewardship: A Stepped-Wedge Randomized Trial. Clinical Infectious Diseases, 2014, 59, 867-874.	2.9	42
12	Evidence based review of escitalopram in treating major depressive disorder in primary care. International Clinical Psychopharmacology, 2004, 19, 305-310.	0.9	40
13	Evidence based information on drug use during pregnancy: a survey of community pharmacists in three countries. International Journal of Clinical Pharmacy, 2001, 23, 76-81.	1.4	25
14	Blood glucose and subsequent cardiovascular disease: update of a meta-analysis. Current Medical Research and Opinion, 2011, 27, 2155-2163.	0.9	25
15	Quality Assessment of Economic Evaluations Published in PharmacoEconomics. Pharmacoeconomics, 1997, 12, 685-694.	1.7	24
16	Clinical and Economic Factors in the Treatment of Behavioural and Psychological Symptoms of Dementia. Drugs and Aging, 2001, 18, 527-550.	1.3	24
17	Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. Journal of Medical Economics, 2001, 4, 137-156.	1.0	24
18	Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. Annals of General Psychiatry, 2012, 11, 18.	1.2	23

THOMAS R EINARSON

#	Article	IF	CITATIONS
19	Utilities for asthma and COPD according to category of severity: a comprehensive literature review. Journal of Medical Economics, 2015, 18, 550-563.	1.0	23
20	Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. Journal of Medical Economics, 2016, 19, 121-130.	1.0	23
21	Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Nordic Journal of Psychiatry, 2014, 68, 416-427.	0.7	22
22	Systematic literature review of the health economic implications of early detection by screening populations at risk for type 2 diabetes. Current Medical Research and Opinion, 2017, 33, 331-358.	0.9	22
23	Clinical and Economic Factors in the Treatment of Onychomycosis. Pharmacoeconomics, 1996, 9, 307-320.	1.7	21
24	Comparative effectiveness of interferons in relapsing–remitting multiple sclerosis: a meta-analysis of real-world studies. Current Medical Research and Opinion, 2017, 33, 579-593.	0.9	21
25	Relationship between blood glucose and carotid intima media thickness: A meta-analysis. Cardiovascular Diabetology, 2010, 9, 37.	2.7	20
26	Economic Evaluation of a New Acellular Vaccine for Pertussis in Canada. Pharmacoeconomics, 2001, 19, 551-563.	1.7	19
27	Dose escalation of biologics in Crohn's disease: critical review of observational studies. Current Medical Research and Opinion, 2017, 33, 1433-1449.	0.9	19
28	Patient preferences in severe COPD and asthma: a comprehensive literature review. International Journal of COPD, 2015, 10, 739.	0.9	18
29	Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. Journal of Medical Economics, 2017, 20, 1187-1199.	1.0	17
30	Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain. Journal of Medical Economics, 2017, 20, 1039-1047.	1.0	17
31	Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway. Acta Neuropsychiatrica, 2013, 25, 85-94.	1.0	16
32	Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. Journal of Medical Economics, 2016, 19, 913-921.	1.0	15
33	Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland. Journal of Medical Economics, 2013, 16, 1096-1105.	1.0	14
34	An Analysis of Potentially Prolactin-Related Adverse Events and Abnormal Prolactin Values in Randomized Clinical Trials with Paliperidone Palmitate. Annals of Pharmacotherapy, 2012, 46, 1322-1330.	0.9	13
35	Prevalence of nausea and vomiting of pregnancy in the USA: a meta analysis. Journal of Population Therapeutics and Clinical Pharmacology, 2013, 20, e163-70.	1.4	13
36	Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic. Journal of Medical Economics, 2013, 16, 1089-1095.	1.0	11

THOMAS R EINARSON

#	Article	IF	CITATIONS
37	Pharmacoeconomic analysis of topical treatments for tinea infections. International Journal of Dermatology, 1998, 37, 64-71.	0.5	9
38	Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective. Breast Cancer: Targets and Therapy, 2012, 4, 173.	1.0	9
39	Meta-Analyses of Cisapride, Omeprazole and Ranitidine in the Treatment of GORD. Clinical Drug Investigation, 1998, 16, 9-18.	1.1	8
40	A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada. Neurology and Therapy, 2012, 1, 1.	1.4	8
41	Quality and content of abstracts in papers reporting about drug exposures during pregnancy. Birth Defects Research Part A: Clinical and Molecular Teratology, 2006, 76, 621-628.	1.6	7
42	Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia. Value in Health Regional Issues, 2013, 2, 181-188.	0.5	7
43	Systematic review of models used in economic analyses in moderate-to-severe asthma and COPD. Journal of Medical Economics, 2016, 19, 319-355.	1.0	6
44	Cost-benefit analysis of pharmacist interventions over 36 months in a university hospital. Revista De Saude Publica, 2020, 54, 94.	0.7	6
45	Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. , 2000, 62, 385.		5
46	The Authority/Pharmacotherapy Care model: an explanatory model of the drug use process in primary care. Research in Social and Administrative Pharmacy, 2005, 1, 101-117.	1.5	4
47	Validation of an economic model of paliperidone palmitate for chronic schizophrenia. Journal of Medical Economics, 2013, 16, 1267-1274.	1.0	3
48	Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. , 2000, 62, 385.		3
49	Corporate Culture and Change. Journal of Pharmaceutical Marketing and Management, 1992, 6, 33-42.	0.1	Ο
50	Sales of Brand-Name Products and Generic Competitors Before and After Market Entry of Product Line Extensions in Canada. Journal of Pharmaceutical Marketing and Management, 2006, 17, 19-37.	0.1	0
51	Cost-benefit analysis of pharmacist interventions over 36 months in a university hospital. Revista De Saude Publica, 2020, 54, 94.	0.7	О